| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cells | 18 | 2022 | 344 | 4.880 |
Why?
|
| Neoplasms | 29 | 2022 | 2106 | 4.510 |
Why?
|
| Leukemia | 9 | 2022 | 209 | 3.930 |
Why?
|
| Aging | 18 | 2022 | 1624 | 3.460 |
Why?
|
| Clonal Evolution | 6 | 2022 | 27 | 2.990 |
Why?
|
| Mutation | 34 | 2022 | 3350 | 2.920 |
Why?
|
| Cell Transformation, Neoplastic | 11 | 2023 | 311 | 2.580 |
Why?
|
| Cell Cycle Proteins | 29 | 2016 | 551 | 2.270 |
Why?
|
| Biological Evolution | 6 | 2020 | 415 | 2.000 |
Why?
|
| Models, Biological | 12 | 2020 | 1636 | 1.990 |
Why?
|
| DNA-Binding Proteins | 32 | 2022 | 1318 | 1.940 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2022 | 636 | 1.900 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2022 | 534 | 1.840 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 4 | 2022 | 43 | 1.790 |
Why?
|
| Fusion Proteins, bcr-abl | 7 | 2015 | 61 | 1.590 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 431 | 1.560 |
Why?
|
| Stem Cells | 10 | 2020 | 546 | 1.530 |
Why?
|
| Selection, Genetic | 9 | 2021 | 243 | 1.440 |
Why?
|
| Animals | 96 | 2023 | 31867 | 1.430 |
Why?
|
| Mice | 67 | 2023 | 14927 | 1.370 |
Why?
|
| Carcinogenesis | 4 | 2022 | 178 | 1.370 |
Why?
|
| Genetic Fitness | 6 | 2021 | 54 | 1.320 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2022 | 787 | 1.310 |
Why?
|
| Apoptosis | 24 | 2022 | 2366 | 1.280 |
Why?
|
| Mutation Rate | 4 | 2019 | 26 | 1.270 |
Why?
|
| Hematopoiesis | 5 | 2022 | 172 | 1.270 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2014 | 94 | 1.250 |
Why?
|
| Transcription Factors | 25 | 2005 | 1531 | 1.220 |
Why?
|
| Down Syndrome | 3 | 2022 | 335 | 1.210 |
Why?
|
| Hematologic Neoplasms | 3 | 2015 | 136 | 1.150 |
Why?
|
| RNA, Small Interfering | 9 | 2016 | 541 | 1.110 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 1045 | 1.100 |
Why?
|
| E2F Transcription Factors | 24 | 2006 | 55 | 1.100 |
Why?
|
| Nuclear Proteins | 10 | 2015 | 593 | 1.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2019 | 963 | 1.070 |
Why?
|
| Adaptation, Physiological | 5 | 2019 | 481 | 1.070 |
Why?
|
| E2F1 Transcription Factor | 20 | 2011 | 57 | 1.030 |
Why?
|
| ErbB Receptors | 5 | 2023 | 555 | 1.010 |
Why?
|
| Cell Proliferation | 16 | 2021 | 2191 | 1.000 |
Why?
|
| Tankyrases | 2 | 2016 | 12 | 0.950 |
Why?
|
| Radiation, Ionizing | 4 | 2015 | 72 | 0.950 |
Why?
|
| Neoplastic Stem Cells | 7 | 2021 | 332 | 0.940 |
Why?
|
| Bone Marrow Transplantation | 7 | 2020 | 241 | 0.920 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 2108 | 0.900 |
Why?
|
| DNA Replication | 9 | 2007 | 202 | 0.890 |
Why?
|
| Humans | 99 | 2023 | 115047 | 0.880 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2013 | 447 | 0.880 |
Why?
|
| Cell Division | 11 | 2020 | 758 | 0.870 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 1879 | 0.870 |
Why?
|
| Lung Neoplasms | 7 | 2023 | 2201 | 0.840 |
Why?
|
| Cellular Senescence | 4 | 2014 | 153 | 0.840 |
Why?
|
| Skin | 5 | 2023 | 659 | 0.840 |
Why?
|
| Cell Line, Tumor | 13 | 2022 | 2715 | 0.830 |
Why?
|
| Dioxygenases | 1 | 2022 | 25 | 0.830 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 10 | 0.830 |
Why?
|
| Clone Cells | 6 | 2023 | 248 | 0.830 |
Why?
|
| Retinoblastoma Protein | 11 | 2006 | 52 | 0.820 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2022 | 26 | 0.810 |
Why?
|
| Models, Genetic | 4 | 2019 | 566 | 0.810 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2015 | 396 | 0.790 |
Why?
|
| Longevity | 2 | 2020 | 137 | 0.790 |
Why?
|
| Glutamine | 2 | 2019 | 91 | 0.770 |
Why?
|
| Cell Cycle | 17 | 2021 | 544 | 0.770 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 34 | 0.760 |
Why?
|
| Tumor Suppressor Proteins | 8 | 2012 | 282 | 0.760 |
Why?
|
| Benzothiazoles | 2 | 2017 | 33 | 0.730 |
Why?
|
| Mice, Transgenic | 15 | 2021 | 1955 | 0.720 |
Why?
|
| Wnt Proteins | 2 | 2012 | 134 | 0.710 |
Why?
|
| Mice, Inbred BALB C | 13 | 2021 | 1153 | 0.700 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 182 | 0.700 |
Why?
|
| Phenylurea Compounds | 2 | 2017 | 82 | 0.690 |
Why?
|
| Carrier Proteins | 16 | 2000 | 696 | 0.680 |
Why?
|
| T-Lymphocytes | 7 | 2016 | 1747 | 0.680 |
Why?
|
| Interleukin-1beta | 2 | 2021 | 370 | 0.680 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 347 | 0.670 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2019 | 697 | 0.660 |
Why?
|
| Oxidation-Reduction | 3 | 2019 | 926 | 0.660 |
Why?
|
| Skin Aging | 1 | 2019 | 19 | 0.650 |
Why?
|
| Precursor Cells, B-Lymphoid | 2 | 2017 | 34 | 0.650 |
Why?
|
| Body Size | 1 | 2019 | 91 | 0.640 |
Why?
|
| Bone Marrow Cells | 4 | 2020 | 267 | 0.640 |
Why?
|
| Mitochondria | 4 | 2019 | 750 | 0.640 |
Why?
|
| Urea | 1 | 2019 | 68 | 0.640 |
Why?
|
| Cell Survival | 8 | 2019 | 1022 | 0.620 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 372 | 0.620 |
Why?
|
| Evolution, Molecular | 4 | 2020 | 437 | 0.620 |
Why?
|
| Phenotype | 9 | 2021 | 2815 | 0.600 |
Why?
|
| RNA Interference | 3 | 2016 | 437 | 0.600 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 309 | 0.600 |
Why?
|
| Benzeneacetamides | 1 | 2017 | 7 | 0.590 |
Why?
|
| Glutaminase | 1 | 2017 | 10 | 0.590 |
Why?
|
| Thiadiazoles | 1 | 2017 | 21 | 0.580 |
Why?
|
| Signal Transduction | 20 | 2021 | 4525 | 0.580 |
Why?
|
| Folic Acid Deficiency | 1 | 2017 | 48 | 0.570 |
Why?
|
| Genetic Vectors | 10 | 2011 | 291 | 0.570 |
Why?
|
| Mice, Inbred C57BL | 19 | 2021 | 4718 | 0.570 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2016 | 63 | 0.570 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 758 | 0.560 |
Why?
|
| Esophagus | 1 | 2019 | 226 | 0.560 |
Why?
|
| Mice, Knockout | 14 | 2021 | 2585 | 0.560 |
Why?
|
| Inflammation | 7 | 2022 | 2485 | 0.550 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 339 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2015 | 115 | 0.550 |
Why?
|
| Adenoviridae | 13 | 2013 | 184 | 0.550 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2016 | 37 | 0.540 |
Why?
|
| Folic Acid | 1 | 2017 | 159 | 0.540 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 49 | 0.540 |
Why?
|
| S Phase | 15 | 2012 | 69 | 0.540 |
Why?
|
| DNA | 7 | 2011 | 1352 | 0.520 |
Why?
|
| Mutagens | 1 | 2015 | 17 | 0.510 |
Why?
|
| Genomics | 4 | 2020 | 641 | 0.510 |
Why?
|
| Islets of Langerhans | 3 | 2008 | 729 | 0.500 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 66 | 0.500 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2015 | 15 | 0.500 |
Why?
|
| Multipotent Stem Cells | 1 | 2015 | 18 | 0.500 |
Why?
|
| Oligomycins | 1 | 2014 | 8 | 0.490 |
Why?
|
| Enzyme Inhibitors | 4 | 2016 | 752 | 0.490 |
Why?
|
| Cell Differentiation | 13 | 2021 | 1700 | 0.490 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 17 | 0.490 |
Why?
|
| Energy Metabolism | 2 | 2019 | 729 | 0.480 |
Why?
|
| Patient-Specific Modeling | 1 | 2014 | 36 | 0.480 |
Why?
|
| Cell Line | 21 | 2021 | 2645 | 0.470 |
Why?
|
| Genes, p53 | 4 | 2012 | 61 | 0.470 |
Why?
|
| Receptors, Notch | 1 | 2015 | 85 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2014 | 1353 | 0.470 |
Why?
|
| Leukemia, Experimental | 2 | 2011 | 27 | 0.460 |
Why?
|
| Cells, Cultured | 13 | 2022 | 3896 | 0.460 |
Why?
|
| Thioguanine | 2 | 2011 | 19 | 0.450 |
Why?
|
| Dietary Supplements | 1 | 2017 | 458 | 0.450 |
Why?
|
| Antigens | 3 | 2005 | 318 | 0.440 |
Why?
|
| Diabetes Mellitus | 3 | 2008 | 906 | 0.440 |
Why?
|
| Receptors, Virus | 4 | 2001 | 75 | 0.430 |
Why?
|
| DNA Repair | 2 | 2012 | 186 | 0.430 |
Why?
|
| Oncogenes | 3 | 2009 | 104 | 0.420 |
Why?
|
| Cytarabine | 1 | 2012 | 51 | 0.390 |
Why?
|
| Mice, Inbred NOD | 4 | 2019 | 559 | 0.390 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2022 | 609 | 0.390 |
Why?
|
| Oxidative Phosphorylation | 3 | 2022 | 156 | 0.390 |
Why?
|
| Cyclin-Dependent Kinases | 9 | 2006 | 111 | 0.370 |
Why?
|
| Myeloproliferative Disorders | 1 | 2011 | 26 | 0.370 |
Why?
|
| Lymphopoiesis | 1 | 2010 | 24 | 0.360 |
Why?
|
| Cell Separation | 2 | 2009 | 291 | 0.360 |
Why?
|
| Adenoviruses, Human | 2 | 2011 | 24 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 1144 | 0.360 |
Why?
|
| Philadelphia Chromosome | 1 | 2010 | 15 | 0.360 |
Why?
|
| Transcription, Genetic | 6 | 2006 | 1317 | 0.360 |
Why?
|
| G1 Phase | 8 | 2002 | 68 | 0.360 |
Why?
|
| Homeostasis | 3 | 2021 | 578 | 0.360 |
Why?
|
| Age Factors | 6 | 2019 | 2894 | 0.350 |
Why?
|
| Gene Expression Regulation | 15 | 2007 | 2329 | 0.350 |
Why?
|
| Bone Marrow | 3 | 2019 | 247 | 0.350 |
Why?
|
| Flow Cytometry | 7 | 2014 | 1084 | 0.350 |
Why?
|
| NFATC Transcription Factors | 1 | 2010 | 78 | 0.350 |
Why?
|
| E2F2 Transcription Factor | 7 | 2008 | 15 | 0.330 |
Why?
|
| Cancer Vaccines | 1 | 2010 | 137 | 0.330 |
Why?
|
| HEK293 Cells | 3 | 2021 | 590 | 0.320 |
Why?
|
| Monte Carlo Method | 2 | 2019 | 137 | 0.320 |
Why?
|
| Blotting, Western | 8 | 2015 | 1149 | 0.310 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2008 | 25 | 0.310 |
Why?
|
| Cellular Microenvironment | 2 | 2020 | 78 | 0.310 |
Why?
|
| CDC2-CDC28 Kinases | 5 | 2002 | 18 | 0.300 |
Why?
|
| Drug Resistance | 1 | 2008 | 158 | 0.300 |
Why?
|
| Trans-Activators | 4 | 2021 | 368 | 0.290 |
Why?
|
| Stem Cell Niche | 3 | 2020 | 42 | 0.290 |
Why?
|
| Purines | 1 | 2008 | 159 | 0.290 |
Why?
|
| Tumor Cells, Cultured | 6 | 2019 | 851 | 0.270 |
Why?
|
| Adenovirus E4 Proteins | 1 | 2006 | 2 | 0.270 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 3545 | 0.270 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2006 | 11 | 0.270 |
Why?
|
| Cyclosporine | 4 | 2014 | 161 | 0.270 |
Why?
|
| Female | 27 | 2021 | 59617 | 0.270 |
Why?
|
| Genes, ras | 2 | 2006 | 91 | 0.260 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 16 | 2000 | 22 | 0.260 |
Why?
|
| Calcium | 2 | 2013 | 1104 | 0.250 |
Why?
|
| Survival Analysis | 2 | 2020 | 1211 | 0.250 |
Why?
|
| Gene Expression | 6 | 2021 | 1423 | 0.250 |
Why?
|
| Pyrimidines | 4 | 2019 | 376 | 0.250 |
Why?
|
| Stochastic Processes | 2 | 2016 | 64 | 0.250 |
Why?
|
| Molecular Sequence Data | 11 | 2015 | 2796 | 0.250 |
Why?
|
| Gamma Rays | 4 | 2020 | 47 | 0.250 |
Why?
|
| Reactive Oxygen Species | 3 | 2019 | 536 | 0.240 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2005 | 383 | 0.240 |
Why?
|
| Phosphorylation | 5 | 2022 | 1572 | 0.240 |
Why?
|
| Quinazolines | 3 | 2016 | 240 | 0.240 |
Why?
|
| DNA Damage | 6 | 2014 | 357 | 0.240 |
Why?
|
| Lymphoma | 3 | 2015 | 178 | 0.230 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 1523 | 0.220 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2010 | 616 | 0.220 |
Why?
|
| Computer Simulation | 2 | 2019 | 881 | 0.210 |
Why?
|
| Cell Lineage | 2 | 2021 | 310 | 0.210 |
Why?
|
| Imatinib Mesylate | 2 | 2014 | 63 | 0.210 |
Why?
|
| Time Factors | 8 | 2017 | 6141 | 0.210 |
Why?
|
| GATA1 Transcription Factor | 1 | 2022 | 13 | 0.210 |
Why?
|
| Thymus Gland | 2 | 2003 | 296 | 0.210 |
Why?
|
| Nucleotides | 2 | 2017 | 112 | 0.210 |
Why?
|
| Everolimus | 1 | 2022 | 61 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 856 | 0.210 |
Why?
|
| DNA Modification Methylases | 1 | 2022 | 14 | 0.200 |
Why?
|
| Gene Transfer Techniques | 4 | 2005 | 147 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2013 | 67 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2003 | 618 | 0.200 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2020 | 171 | 0.200 |
Why?
|
| Monocytes | 2 | 2022 | 503 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2012 | 744 | 0.200 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2021 | 7 | 0.190 |
Why?
|
| Transfection | 6 | 2005 | 872 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 520 | 0.190 |
Why?
|
| Enterovirus | 2 | 2005 | 72 | 0.190 |
Why?
|
| Macrophages | 1 | 2008 | 1267 | 0.190 |
Why?
|
| Immunity, Innate | 3 | 2021 | 723 | 0.190 |
Why?
|
| Disease Progression | 3 | 2020 | 2389 | 0.190 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2012 | 81 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 928 | 0.190 |
Why?
|
| Glycolysis | 2 | 2019 | 227 | 0.180 |
Why?
|
| Aged | 5 | 2022 | 19122 | 0.180 |
Why?
|
| Lymphocytes | 2 | 2001 | 334 | 0.180 |
Why?
|
| Air Pollution | 1 | 2023 | 170 | 0.180 |
Why?
|
| Risk Factors | 4 | 2022 | 8642 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 56 | 0.180 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 89 | 0.180 |
Why?
|
| Genotype | 4 | 2014 | 1780 | 0.180 |
Why?
|
| Securin | 1 | 2020 | 2 | 0.180 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 56 | 0.180 |
Why?
|
| Whole-Body Irradiation | 1 | 2020 | 72 | 0.180 |
Why?
|
| Myeloid Cells | 1 | 2021 | 127 | 0.170 |
Why?
|
| Air Pollutants | 1 | 2023 | 244 | 0.170 |
Why?
|
| Aneuploidy | 1 | 2020 | 86 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 358 | 0.170 |
Why?
|
| Amino Acid Sequence | 6 | 2015 | 1990 | 0.170 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 144 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2013 | 228 | 0.170 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 31 | 0.170 |
Why?
|
| False Positive Reactions | 1 | 2019 | 109 | 0.170 |
Why?
|
| Single Molecule Imaging | 1 | 2019 | 29 | 0.170 |
Why?
|
| Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 2019 | 5 | 0.160 |
Why?
|
| Survival Rate | 2 | 2020 | 1646 | 0.160 |
Why?
|
| Gene Library | 1 | 2019 | 114 | 0.160 |
Why?
|
| Electron Transport Complex II | 1 | 2019 | 23 | 0.160 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2016 | 174 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2003 | 637 | 0.160 |
Why?
|
| Population Density | 1 | 2019 | 94 | 0.160 |
Why?
|
| Cell Respiration | 1 | 2019 | 74 | 0.160 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 104 | 0.160 |
Why?
|
| Drug Synergism | 2 | 2016 | 317 | 0.160 |
Why?
|
| Autophagy | 1 | 2021 | 234 | 0.160 |
Why?
|
| Cytokines | 3 | 2015 | 1843 | 0.160 |
Why?
|
| Cause of Death | 1 | 2020 | 364 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 1138 | 0.160 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 60 | 0.160 |
Why?
|
| Stress, Physiological | 1 | 2021 | 377 | 0.150 |
Why?
|
| Cysteine | 1 | 2019 | 171 | 0.150 |
Why?
|
| Leukocytes | 1 | 2019 | 277 | 0.150 |
Why?
|
| Epithelium | 1 | 2019 | 297 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 385 | 0.150 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 389 | 0.150 |
Why?
|
| Wnt Signaling Pathway | 2 | 2016 | 147 | 0.150 |
Why?
|
| Prognosis | 3 | 2022 | 3334 | 0.150 |
Why?
|
| Metabolism | 1 | 2017 | 35 | 0.150 |
Why?
|
| Dasatinib | 3 | 2014 | 46 | 0.150 |
Why?
|
| Transcription Factor DP1 | 12 | 2000 | 21 | 0.150 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 617 | 0.150 |
Why?
|
| Rad51 Recombinase | 2 | 2007 | 14 | 0.150 |
Why?
|
| Heredity | 1 | 2017 | 12 | 0.140 |
Why?
|
| Bromodeoxyuridine | 5 | 2005 | 72 | 0.140 |
Why?
|
| Thiazoles | 3 | 2014 | 110 | 0.140 |
Why?
|
| RNA, Messenger | 5 | 2015 | 2563 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2016 | 226 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 107 | 0.140 |
Why?
|
| Hydrazines | 1 | 2016 | 28 | 0.140 |
Why?
|
| Hydroxyurea | 2 | 2007 | 30 | 0.140 |
Why?
|
| Tumor Protein p73 | 3 | 2006 | 14 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 999 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 157 | 0.140 |
Why?
|
| Interleukin-1 | 1 | 2021 | 970 | 0.140 |
Why?
|
| Blood Platelets | 1 | 2019 | 352 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2010 | 58 | 0.130 |
Why?
|
| Carbazoles | 1 | 2016 | 80 | 0.130 |
Why?
|
| Serine Endopeptidases | 1 | 2016 | 102 | 0.130 |
Why?
|
| Middle Aged | 5 | 2020 | 26830 | 0.130 |
Why?
|
| Thrombosis | 1 | 2019 | 301 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2019 | 204 | 0.130 |
Why?
|
| Recombination, Genetic | 4 | 2007 | 176 | 0.130 |
Why?
|
| Glutamic Acid | 1 | 2017 | 211 | 0.130 |
Why?
|
| Biopsy | 1 | 2019 | 1046 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2018 | 385 | 0.130 |
Why?
|
| Pedigree | 1 | 2017 | 467 | 0.130 |
Why?
|
| Interphase | 1 | 1995 | 32 | 0.130 |
Why?
|
| Genetic Drift | 1 | 2015 | 7 | 0.130 |
Why?
|
| Open Reading Frames | 1 | 2016 | 116 | 0.130 |
Why?
|
| Protein Isoforms | 3 | 2009 | 339 | 0.130 |
Why?
|
| DNA Polymerase II | 1 | 1995 | 37 | 0.130 |
Why?
|
| Interferons | 1 | 2016 | 150 | 0.130 |
Why?
|
| Piperidines | 1 | 2016 | 162 | 0.120 |
Why?
|
| Embryonic and Fetal Development | 2 | 2000 | 94 | 0.120 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2015 | 16 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2019 | 464 | 0.120 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.120 |
Why?
|
| Ketone Oxidoreductases | 1 | 2014 | 7 | 0.120 |
Why?
|
| Amino Acids | 1 | 2018 | 451 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 2019 | 529 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 1715 | 0.120 |
Why?
|
| Biomarkers | 6 | 2021 | 3419 | 0.120 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 55 | 0.120 |
Why?
|
| Exome | 1 | 2016 | 201 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 315 | 0.120 |
Why?
|
| Phosphoproteins | 3 | 2003 | 298 | 0.120 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 87 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 5 | 2011 | 1133 | 0.120 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2010 | 477 | 0.120 |
Why?
|
| Ovalbumin | 2 | 2005 | 162 | 0.120 |
Why?
|
| Metabolomics | 1 | 2019 | 527 | 0.120 |
Why?
|
| Pancreas | 2 | 2008 | 280 | 0.120 |
Why?
|
| Calcineurin Inhibitors | 1 | 2014 | 58 | 0.120 |
Why?
|
| Superoxides | 1 | 2014 | 214 | 0.110 |
Why?
|
| Fibroblasts | 4 | 2016 | 839 | 0.110 |
Why?
|
| Gastrula | 1 | 1994 | 21 | 0.110 |
Why?
|
| Genome, Human | 2 | 2016 | 351 | 0.110 |
Why?
|
| Models, Molecular | 3 | 2010 | 1379 | 0.110 |
Why?
|
| Salivary Glands | 1 | 2014 | 31 | 0.110 |
Why?
|
| Risk | 1 | 2016 | 815 | 0.110 |
Why?
|
| GTPase-Activating Proteins | 1 | 1994 | 71 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 955 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 167 | 0.110 |
Why?
|
| Genes | 1 | 1994 | 224 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2016 | 362 | 0.110 |
Why?
|
| Urothelium | 1 | 2013 | 33 | 0.110 |
Why?
|
| Base Sequence | 10 | 2004 | 2119 | 0.110 |
Why?
|
| Smoking | 1 | 2020 | 1392 | 0.110 |
Why?
|
| Protein Kinase C-delta | 1 | 2014 | 70 | 0.110 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2013 | 2 | 0.110 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1994 | 82 | 0.110 |
Why?
|
| Pyridines | 1 | 2016 | 426 | 0.110 |
Why?
|
| Adenoma | 1 | 2015 | 187 | 0.110 |
Why?
|
| Retroviridae | 3 | 2004 | 90 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2021 | 691 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 220 | 0.110 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2013 | 63 | 0.100 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 19 | 0.100 |
Why?
|
| Child | 4 | 2022 | 18407 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 3 | 2010 | 798 | 0.100 |
Why?
|
| Cyclin E | 6 | 2005 | 21 | 0.100 |
Why?
|
| Transduction, Genetic | 3 | 2001 | 113 | 0.100 |
Why?
|
| Algorithms | 1 | 2019 | 1489 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 137 | 0.100 |
Why?
|
| Lymphocyte Activation | 3 | 2005 | 1042 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 1901 | 0.100 |
Why?
|
| Cyclins | 3 | 1997 | 78 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2015 | 368 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 476 | 0.100 |
Why?
|
| Sarcoma | 1 | 2013 | 137 | 0.100 |
Why?
|
| E2F3 Transcription Factor | 3 | 2002 | 8 | 0.100 |
Why?
|
| Male | 13 | 2021 | 55735 | 0.100 |
Why?
|
| Proteins | 2 | 1996 | 915 | 0.100 |
Why?
|
| Piperazines | 2 | 2012 | 313 | 0.100 |
Why?
|
| Mice, Nude | 2 | 2012 | 631 | 0.100 |
Why?
|
| Urinary Bladder | 1 | 2013 | 163 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2976 | 0.100 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 46 | 0.090 |
Why?
|
| Cell Movement | 1 | 2015 | 866 | 0.090 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 300 | 0.090 |
Why?
|
| Interleukin-7 | 1 | 2010 | 45 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 32 | 0.090 |
Why?
|
| Vaccines, Synthetic | 1 | 2010 | 125 | 0.090 |
Why?
|
| Benzamides | 1 | 2010 | 168 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 386 | 0.080 |
Why?
|
| Cyclophilin A | 1 | 2009 | 24 | 0.080 |
Why?
|
| Basigin | 1 | 2009 | 25 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2011 | 258 | 0.080 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 179 | 0.080 |
Why?
|
| Genes, Retinoblastoma | 3 | 2006 | 8 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6357 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2004 | 78 | 0.080 |
Why?
|
| Conserved Sequence | 2 | 2003 | 218 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 617 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2005 | 965 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 427 | 0.080 |
Why?
|
| Lentivirus | 1 | 2008 | 45 | 0.080 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2008 | 11 | 0.080 |
Why?
|
| Publishing | 1 | 2009 | 125 | 0.080 |
Why?
|
| Protein Kinases | 2 | 2007 | 307 | 0.070 |
Why?
|
| Luminescent Proteins | 3 | 2004 | 165 | 0.070 |
Why?
|
| Protein Folding | 1 | 2009 | 239 | 0.070 |
Why?
|
| Rats | 7 | 2007 | 4973 | 0.070 |
Why?
|
| Recombinant Proteins | 6 | 2009 | 1237 | 0.070 |
Why?
|
| Pancreatitis, Chronic | 1 | 2008 | 40 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase 2 | 5 | 2002 | 32 | 0.070 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Aphidicolin | 1 | 2007 | 6 | 0.070 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2007 | 28 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 1 | 2008 | 299 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 3 | 2004 | 373 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2008 | 107 | 0.070 |
Why?
|
| Keratinocytes | 3 | 2005 | 216 | 0.070 |
Why?
|
| Etoposide | 1 | 2007 | 148 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2010 | 383 | 0.070 |
Why?
|
| Protein Binding | 3 | 2014 | 1898 | 0.070 |
Why?
|
| Substantia Nigra | 1 | 2007 | 37 | 0.070 |
Why?
|
| Th2 Cells | 2 | 2005 | 155 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2007 | 812 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2010 | 474 | 0.070 |
Why?
|
| Organ Specificity | 3 | 2016 | 270 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 651 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2020 | 445 | 0.070 |
Why?
|
| Interneurons | 1 | 2007 | 96 | 0.070 |
Why?
|
| Environmental Pollutants | 1 | 2007 | 110 | 0.070 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 3 | 2001 | 7 | 0.060 |
Why?
|
| Flavonoids | 2 | 2003 | 68 | 0.060 |
Why?
|
| Genes, Fungal | 2 | 1996 | 49 | 0.060 |
Why?
|
| Mice, Inbred DBA | 1 | 2005 | 173 | 0.060 |
Why?
|
| Skin Transplantation | 1 | 2005 | 57 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 772 | 0.060 |
Why?
|
| ras Proteins | 2 | 2013 | 138 | 0.060 |
Why?
|
| Genes, abl | 1 | 2004 | 3 | 0.060 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2005 | 131 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 276 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 2003 | 524 | 0.060 |
Why?
|
| Ultraviolet Rays | 2 | 2005 | 368 | 0.060 |
Why?
|
| Blotting, Northern | 4 | 2003 | 193 | 0.060 |
Why?
|
| Spleen | 2 | 2005 | 486 | 0.060 |
Why?
|
| Drosophila melanogaster | 1 | 2005 | 191 | 0.060 |
Why?
|
| Polyploidy | 1 | 2003 | 16 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2015 | 353 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2016 | 1019 | 0.060 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 100 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2007 | 524 | 0.050 |
Why?
|
| Genes, Lethal | 2 | 2012 | 26 | 0.050 |
Why?
|
| Erythropoiesis | 1 | 2003 | 34 | 0.050 |
Why?
|
| Chromatin | 2 | 2004 | 428 | 0.050 |
Why?
|
| Immunologic Memory | 1 | 2005 | 313 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2005 | 297 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2003 | 10 | 0.050 |
Why?
|
| Mutagenesis, Insertional | 2 | 1994 | 61 | 0.050 |
Why?
|
| Neomycin | 1 | 2003 | 7 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 1998 | 333 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2007 | 323 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2003 | 67 | 0.050 |
Why?
|
| Graft Survival | 1 | 2005 | 464 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2003 | 272 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1865 | 0.050 |
Why?
|
| beta-Galactosidase | 2 | 2013 | 62 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2003 | 133 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 390 | 0.050 |
Why?
|
| Eukaryotic Cells | 1 | 2002 | 33 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2003 | 170 | 0.050 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2023 | 96 | 0.050 |
Why?
|
| Gene Targeting | 1 | 2002 | 75 | 0.050 |
Why?
|
| Particle Size | 1 | 2023 | 317 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2001 | 52 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2023 | 185 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2002 | 100 | 0.050 |
Why?
|
| Autophagosomes | 1 | 2021 | 19 | 0.050 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2002 | 68 | 0.050 |
Why?
|
| Adenovirus E2 Proteins | 1 | 2000 | 1 | 0.050 |
Why?
|
| Drosophila | 1 | 2002 | 133 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1036 | 0.050 |
Why?
|
| Autophagy-Related Proteins | 1 | 2021 | 39 | 0.050 |
Why?
|
| Cell Nucleus | 3 | 2014 | 556 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2001 | 54 | 0.040 |
Why?
|
| Biological Assay | 1 | 2021 | 113 | 0.040 |
Why?
|
| Lysosomes | 1 | 2021 | 123 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 2007 | 292 | 0.040 |
Why?
|
| Prolactin | 1 | 2000 | 95 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2000 | 114 | 0.040 |
Why?
|
| Niacinamide | 1 | 2020 | 62 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2000 | 144 | 0.040 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2019 | 2 | 0.040 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 1999 | 6 | 0.040 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2002 | 180 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2007 | 1634 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2023 | 351 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2019 | 40 | 0.040 |
Why?
|
| Superantigens | 1 | 1999 | 69 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2023 | 4904 | 0.040 |
Why?
|
| Adipocytes | 1 | 2001 | 189 | 0.040 |
Why?
|
| Ribonucleoproteins | 1 | 2000 | 86 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 2019 | 30 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2023 | 377 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2005 | 956 | 0.040 |
Why?
|
| Embryonic Development | 1 | 2000 | 117 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2003 | 668 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 1997 | 69 | 0.040 |
Why?
|
| Succinate Dehydrogenase | 1 | 2019 | 42 | 0.040 |
Why?
|
| Nanog Homeobox Protein | 1 | 2019 | 11 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2001 | 422 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2002 | 269 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2019 | 68 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2003 | 635 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 1999 | 176 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2001 | 344 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 1998 | 21 | 0.040 |
Why?
|
| RNA | 2 | 2003 | 810 | 0.040 |
Why?
|
| Integrases | 2 | 2013 | 116 | 0.040 |
Why?
|
| Thymoma | 1 | 1998 | 30 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 1998 | 58 | 0.040 |
Why?
|
| Mitosis | 2 | 1999 | 164 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 398 | 0.040 |
Why?
|
| Sarcopenia | 1 | 2019 | 63 | 0.040 |
Why?
|
| Doxorubicin | 1 | 1999 | 285 | 0.040 |
Why?
|
| fas Receptor | 1 | 1998 | 92 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 340 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 396 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 319 | 0.040 |
Why?
|
| Cell Physiological Phenomena | 1 | 1997 | 23 | 0.040 |
Why?
|
| Glutathione | 1 | 2019 | 302 | 0.040 |
Why?
|
| Dexamethasone | 1 | 1999 | 317 | 0.040 |
Why?
|
| Biological Transport | 1 | 2018 | 372 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 213 | 0.040 |
Why?
|
| Azacitidine | 1 | 2018 | 129 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3015 | 0.040 |
Why?
|
| Frailty | 1 | 2019 | 115 | 0.040 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 1996 | 15 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 431 | 0.030 |
Why?
|
| Restriction Mapping | 2 | 1994 | 77 | 0.030 |
Why?
|
| 3T3 Cells | 3 | 2004 | 140 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 524 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1998 | 429 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2019 | 330 | 0.030 |
Why?
|
| Phylogeny | 1 | 2020 | 796 | 0.030 |
Why?
|
| G2 Phase | 1 | 1995 | 31 | 0.030 |
Why?
|
| Metabolome | 1 | 2018 | 285 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 449 | 0.030 |
Why?
|
| Thymidylate Synthase | 1 | 1995 | 11 | 0.030 |
Why?
|
| Ribonucleotide Reductases | 1 | 1995 | 21 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1995 | 49 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 273 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 676 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2015 | 49 | 0.030 |
Why?
|
| Twist-Related Protein 1 | 1 | 2015 | 10 | 0.030 |
Why?
|
| Plasmids | 1 | 1995 | 345 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2003 | 1821 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1994 | 24 | 0.030 |
Why?
|
| alpha Karyopherins | 1 | 2014 | 13 | 0.030 |
Why?
|
| Cyclin A | 2 | 2005 | 15 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2016 | 296 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2014 | 95 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 152 | 0.030 |
Why?
|
| Insulin | 1 | 2003 | 2082 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 175 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 370 | 0.030 |
Why?
|
| Arginine | 1 | 2015 | 238 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1591 | 0.030 |
Why?
|
| Ectoderm | 1 | 1994 | 43 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2014 | 168 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2014 | 110 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 442 | 0.030 |
Why?
|
| Breeding | 1 | 2013 | 55 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 129 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2014 | 88 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 1994 | 119 | 0.030 |
Why?
|
| Leucine | 1 | 1994 | 107 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 156 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1994 | 325 | 0.030 |
Why?
|
| Tyrosine | 1 | 2014 | 216 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2013 | 135 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 1994 | 131 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2013 | 165 | 0.030 |
Why?
|
| Keratins | 1 | 2013 | 176 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 68 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 441 | 0.030 |
Why?
|
| Neurons | 1 | 2000 | 1284 | 0.030 |
Why?
|
| Wound Healing | 1 | 2015 | 259 | 0.030 |
Why?
|
| Genes, Synthetic | 1 | 2012 | 14 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2014 | 356 | 0.030 |
Why?
|
| RNA, Untranslated | 1 | 2013 | 113 | 0.030 |
Why?
|
| Proviruses | 2 | 2003 | 9 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2013 | 124 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2013 | 213 | 0.020 |
Why?
|
| Virus Integration | 2 | 2003 | 68 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 229 | 0.020 |
Why?
|
| Moloney murine leukemia virus | 1 | 1991 | 11 | 0.020 |
Why?
|
| Imidazoles | 1 | 2012 | 209 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 1991 | 67 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2002 | 257 | 0.020 |
Why?
|
| Ear | 1 | 2011 | 32 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2015 | 496 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1991 | 104 | 0.020 |
Why?
|
| RNA, Viral | 1 | 1994 | 567 | 0.020 |
Why?
|
| Down-Regulation | 2 | 2003 | 599 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 4420 | 0.020 |
Why?
|
| DNA Probes | 2 | 2002 | 59 | 0.020 |
Why?
|
| Syndecan-1 | 1 | 2009 | 27 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 937 | 0.020 |
Why?
|
| Catalysis | 1 | 2009 | 292 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2009 | 325 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2000 | 791 | 0.020 |
Why?
|
| Cell Line, Transformed | 2 | 2002 | 133 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2009 | 188 | 0.020 |
Why?
|
| Mammals | 2 | 2002 | 245 | 0.020 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2007 | 2 | 0.020 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 2007 | 5 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2009 | 590 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2007 | 100 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2799 | 0.020 |
Why?
|
| HeLa Cells | 2 | 1998 | 562 | 0.020 |
Why?
|
| Cyclin B | 1 | 2005 | 13 | 0.020 |
Why?
|
| Mitomycin | 1 | 2005 | 27 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2005 | 47 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 474 | 0.020 |
Why?
|
| Kinetics | 2 | 2000 | 1558 | 0.020 |
Why?
|
| Cytosol | 1 | 2005 | 208 | 0.010 |
Why?
|
| Cornea | 1 | 2005 | 107 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2005 | 135 | 0.010 |
Why?
|
| Aldehydes | 1 | 2005 | 142 | 0.010 |
Why?
|
| GATA3 Transcription Factor | 1 | 2004 | 24 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 305 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 1229 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 930 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2015 | 6232 | 0.010 |
Why?
|
| United States | 1 | 2019 | 12227 | 0.010 |
Why?
|
| Acetylation | 1 | 2004 | 211 | 0.010 |
Why?
|
| Transgenes | 1 | 2004 | 170 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 128 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2003 | 34 | 0.010 |
Why?
|
| Caspases | 1 | 2004 | 245 | 0.010 |
Why?
|
| Sunlight | 1 | 2003 | 57 | 0.010 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2002 | 5 | 0.010 |
Why?
|
| Polyadenylation | 1 | 2003 | 37 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2002 | 127 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3118 | 0.010 |
Why?
|
| Centrosome | 1 | 2002 | 59 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 80 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 2002 | 51 | 0.010 |
Why?
|
| Thymidine | 1 | 2002 | 58 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2004 | 281 | 0.010 |
Why?
|
| RNA Splicing | 1 | 2003 | 246 | 0.010 |
Why?
|
| Integrin alphaV | 1 | 2001 | 4 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 23 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2000 | 23 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2000 | 15 | 0.010 |
Why?
|
| Ganglia, Spinal | 1 | 2000 | 41 | 0.010 |
Why?
|
| Receptors, Prolactin | 1 | 2000 | 8 | 0.010 |
Why?
|
| Capsid | 1 | 2001 | 75 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 69 | 0.010 |
Why?
|
| Granulocytes | 1 | 2000 | 77 | 0.010 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2000 | 3 | 0.010 |
Why?
|
| Blastomeres | 1 | 2000 | 12 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 9123 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2000 | 95 | 0.010 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2000 | 19 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2000 | 146 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2000 | 164 | 0.010 |
Why?
|
| Antibodies | 1 | 2002 | 372 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 310 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 503 | 0.010 |
Why?
|
| Histones | 1 | 2004 | 535 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 278 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1999 | 43 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 1085 | 0.010 |
Why?
|
| Genes, myc | 1 | 1999 | 46 | 0.010 |
Why?
|
| Species Specificity | 1 | 2000 | 548 | 0.010 |
Why?
|
| Half-Life | 1 | 1999 | 143 | 0.010 |
Why?
|
| Minichromosome Maintenance Complex Component 3 | 1 | 1998 | 2 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2001 | 441 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 172 | 0.010 |
Why?
|
| Sheep | 1 | 2000 | 764 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1998 | 56 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1997 | 27 | 0.010 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 1996 | 2 | 0.010 |
Why?
|
| Autoradiography | 1 | 1997 | 70 | 0.010 |
Why?
|
| Origin Recognition Complex | 1 | 1996 | 3 | 0.010 |
Why?
|
| Cyclin D | 1 | 1996 | 5 | 0.010 |
Why?
|
| Pregnancy | 2 | 2000 | 5520 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 317 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 1996 | 33 | 0.010 |
Why?
|
| Genomic Library | 1 | 1995 | 15 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 1996 | 37 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1995 | 195 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1995 | 138 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1995 | 345 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1995 | 174 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1996 | 212 | 0.010 |
Why?
|
| Adult | 1 | 2014 | 30658 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 5040 | 0.010 |
Why?
|
| Kanamycin Kinase | 1 | 1992 | 4 | 0.010 |
Why?
|
| Binding Sites | 1 | 1995 | 1173 | 0.010 |
Why?
|
| Phosphotransferases | 1 | 1992 | 25 | 0.010 |
Why?
|
| Chimera | 1 | 1992 | 59 | 0.010 |
Why?
|
| Alcohol Oxidoreductases | 1 | 1992 | 38 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 17864 | 0.010 |
Why?
|
| Adenovirus Early Proteins | 1 | 1991 | 2 | 0.010 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 1991 | 14 | 0.010 |
Why?
|
| Mesocricetus | 1 | 1991 | 30 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1991 | 49 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1991 | 62 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 1991 | 35 | 0.010 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1991 | 20 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1991 | 68 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1991 | 82 | 0.010 |
Why?
|
| Cricetinae | 1 | 1991 | 259 | 0.010 |
Why?
|
| Poly A | 1 | 1991 | 46 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1991 | 151 | 0.010 |
Why?
|
| Methionine | 1 | 1991 | 145 | 0.010 |
Why?
|
| Placenta | 1 | 1995 | 624 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1991 | 719 | 0.000 |
Why?
|